This is a StreetInsider.com Premium Only Page

Abiomed (ABMD) – Company Press Releases

Dec 21, 2022 09:00 AM FDA Approves Impella ECP Pivotal Heart Pump and First Patients Enrolled in Pivotal Clinical Trial

Dec 19, 2022 06:35 PM Steel Dynamics Set to Join S&P 500; Super Micro Computer to Join S&P MidCap 400

Dec 14, 2022 07:15 AM Johnson & Johnson Announces Extension of Abiomed Tender Offer to December 21, 2022

Dec 5, 2022 08:03 AM First Patients in the World Treated with Impella RP Flex with SmartAssist

Nov 14, 2022 04:09 PM Azenta Announces Nomination of Tina S. Nova, Ph.D. and Dorothy E. Puhy to Board of Directors

Nov 1, 2022 07:00 AM Abiomed Announces Second Quarter Revenue of $266 Million, up 11% in Constant Currency*, up 7% on a Reported Basis Year Over Year

Nov 1, 2022 06:30 AM Johnson & Johnson to Acquire Abiomed

Oct 31, 2022 08:02 AM Impella RP Flex with SmartAssist Receives FDA Approval to Treat Right Heart Failure

Oct 26, 2022 08:02 AM  Abiomed Creates Patient Assistance Program to Address Disparities in Healthcare

Oct 24, 2022 12:00 PM MedTechVets Appoints Patrice Sutherland, Enterprise Executive Director at Integra LifeScience, as New Board Chairperson

Oct 20, 2022 10:24 AM Abiomed Successfully Completes All Impella Post-Approval Studies for High-Risk PCI, Cardiogenic Shock, Post-Cardiotomy Cardiogenic Shock and Right Heart Failure

Oct 17, 2022 07:58 AM U.S. FDA Grants 510(k) Clearance for Impella Low Profile Sheath

Oct 13, 2022 08:02 AM Yale University Study Demonstrates Significant Survival Benefit in High-Risk PCI with Impella Support

Oct 13, 2022 07:00 AM Abiomed Second Quarter Fiscal 2023 Earnings and Conference Call Notification

Sep 20, 2022 08:02 AM Multi-Center, Multi-Society Study of Impella-supported Patients with Cardiogenic Shock due to Myocarditis in Japan Achieves 30-day Survival of 77%

Sep 19, 2022 08:02 AM Large, Multi-Center, Multi-Society Study of Impella-supported Patients Finds 30-day AMI Cardiogenic Shock Survival of 81%

Sep 17, 2022 09:02 AM Unloading with Impella for 30 Minutes Before PCI Associated with Reduced Infarct Size in STEMI Patients

Sep 16, 2022 08:03 AM FDA Approves RECOVER IV Randomized Controlled Trial with Exception from Informed Consent (EFIC)

Sep 13, 2022 08:02 AM TCT 2022: Impella Enables Complete Revascularization, Improved Quality of Life and Native Heart Recovery

Aug 16, 2022 08:02 AM Restore EF Study Shows Heart Function, Symptom Improvements for High-Risk PCI Patients Supported by Impella

Aug 4, 2022 07:00 AM ABIOMED Announces First Quarter Record Revenue of $277 Million, up 10% Year Over Year, up 12% in Constant Currency*

Jul 14, 2022 07:00 AM Abiomed First Quarter Fiscal 2023 Earnings and Conference Call Notification

Jun 14, 2022 04:30 PM Abiomed to Host Investor Call on Heart Failure Opportunity With Impella 5.5 and Impella BTR Heart Pumps

May 31, 2022 07:00 AM Abiomed to Present (Live) at the William Blair 42nd Annual Growth Stock Conference

May 18, 2022 08:03 AM SCAI 2022 Scientific Sessions Highlight Impella Research, Advancements to Improve Cardiogenic Shock Outcomes

Apr 28, 2022 07:00 AM Abiomed Announces Fourth Quarter Record Revenue of $270 Million, up 12% Year Over Year

Apr 26, 2022 08:02 AM World’s First Patient Implanted with Impella BTR Minimally Invasive Heart Pump

Apr 8, 2022 07:00 AM Abiomed Fourth Quarter Fiscal 2022 Earnings and Conference Call Notification

Apr 6, 2022 08:04 AM First Patient in Japan Treated with Impella 5.5 with SmartAssist

Mar 21, 2022 07:00 AM Abiomed to Host Investor Call on Impella ECP, the World’s Smallest Heart Pump at 9 French

Feb 8, 2022 04:05 PM Abiomed to Present at the SVB Leerink 11th Annual Global Healthcare Conference

Feb 3, 2022 07:00 AM Abiomed Announces Record Revenue of $261 Million, up 13% Year Over Year

Jan 14, 2022 07:00 AM Abiomed Third Quarter Fiscal 2022 Earnings and Conference Call Notification

Jan 12, 2022 08:03 AM Early Feasibility Study Demonstrates Successful Use of Abiomed’s preCARDIA Technology

Jan 10, 2022 08:02 AM Regulators Approve Impella 5.5 With SmartAssist in Japan and Hong Kong; US FDA Grants Impella BTR Conditional IDE Approval for First-in-Human Early Feasibility Study

Dec 29, 2021 07:00 AM Abiomed to Present at the 40th Annual J.P. Morgan Healthcare Conference

Nov 18, 2021 07:00 AM Abiomed to Present at Upcoming Investor Conferences

Nov 4, 2021 08:05 AM Two Large Studies Demonstrate Complete Revascularization with Impella Heart Pumps Improves Ejection Fraction and Long-Term Patient Outcomes

Nov 3, 2021 08:02 AM Impella Advances to Higher Level of Recommendation in Newest ESC Guidelines

Nov 1, 2021 07:58 AM TCT 2021 to Highlight Improved Patient Outcomes with Impella’s Small, Smart and Connected Technology

Oct 28, 2021 07:00 AM Abiomed Announces Q2 FY 2022 Revenue of $248 Million, Up 18% Year Over Year

Oct 7, 2021 07:00 AM Abiomed Second Quarter Fiscal 2022 Earnings and Conference Call Notification

Aug 18, 2021 08:02 AM FDA Grants Breakthrough Device Designation to Impella ECP, the World’s Smallest Heart Pump

Aug 4, 2021 04:15 PM Abiomed Announces Record Revenue of $253 Million, Up 53% Year Over Year

Jul 15, 2021 07:00 AM Abiomed First Quarter Fiscal 2022 Earnings and Conference Call Notification

Jun 29, 2021 08:03 AM FDA Grants Highest Level of Approval to the Next Generation of Impella RP to Treat Right Heart Failure

Jun 1, 2021 08:03 AM  Abiomed Acquires preCARDIA, a Breakthrough Medical Device Company, to Improve Outcomes for Heart Failure Patients

May 25, 2021 07:00 AM Abiomed to Present at Upcoming Investor Conferences

Apr 29, 2021 07:00 AM Abiomed Announces Record Revenue of $241 Million, up 17% Year Over Year, With 26.0% Operating Margin

Apr 28, 2021 03:57 PM Final Results from the National Cardiogenic Shock Initiative (NCSI) Study Demonstrate the Benefit of Early Cardiac Unloading with Impella